Five Prime Therapeutics (NASDAQ:FPRX) managed to stay afloat and traded higher with an addition of 0.69 point or 1.64% at $42.87. The money flow data is a negative $(-4.93) million with $4.07 million in upticks and $9 million in downticks. The intraday up/down ratio came in at 0.45. The shares have seen 1.4% change for the week in its share price.From the data available, it was found that a block transaction occurred during the course of trading. For it, the aggregated worth of the upticks was $0 million and the combined worth of the downticks was $5.49, Million, leading to the up/down ratio of 0. The block trade saw a net money flow of $(-5.49) million.
Currently the company Insiders own 5.3% of Five Prime Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 15.01% . Institutional Investors own 82.16% of Five Prime Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of 15.01%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Belsky Marc, officer (Senior Vice President and CFO) of Five Prime Therapeutics Inc, had unloaded 34,102 shares at an average price of $49.63 in a transaction dated on April 22, 2016. The total value of the transaction was worth $1,692,482.
Five Prime Therapeutics (NASDAQ:FPRX) : On Monday heightened volatility was witnessed in Five Prime Therapeutics (NASDAQ:FPRX) which led to swings in the share price. The stock opened for trading at $42.99 and hit $43.89 on the upside , eventually ending the session at $42.93, with a gain of 0.14% or 0.06 points. The heightened volatility saw the trading volume jump to 481,082 shares. The 52-week high of the share price is $50.11 and the company has a market cap of $1,211 million. The 52-week low of the share price is at $14.7 .
Many analysts have stated their opinion on the company shares. BMO Capital initiates coverage on Five Prime Therapeutics (NASDAQ:FPRX).The analysts at the brokerage house have a current rating of Market Perform on the shares. In a recent information released to the investors, BMO Capital announces the price target of $50 per share. The rating by the firm was issued on April 12, 2016.
Five Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Companys product candidates include FPA008, FPA144 and FP-1039/GSK3052230. FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R), that the Company is developing in rheumatoid arthritis. FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b), which the Company is developing to treat patients with gastric cancer. FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. Its partner, GlaxoSmithKline is developing FP-1039/GSK3052230 to treat patients with squamous non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma.